MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

MDT

100.48

+1.87%↑

A

139.65

+3%↑

VEEV

219.8

+1.79%↑

HQY

84.32

+0.78%↑

NEOG

9.86

+5.45%↑

Search

Champions Oncology Inc

Aperta

SettoreSettore sanitario

6.47 0.31

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

6.45

Massimo

7.07

Metriche Chiave

By Trading Economics

Entrata

702K

236K

Vendite

1M

15M

P/E

Media del settore

42.412

89.037

Margine di Profitto

1.57

Dipendenti

213

EBITDA

1.1M

612K

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+71.43% upside

Dividendi

By Dow Jones

Utili prossimi

10 mar 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-7.4M

100M

Apertura precedente

6.16

Chiusura precedente

6.47

Notizie sul Sentiment di mercato

By Acuity

50%

50%

177 / 360 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Champions Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

21 gen 2026, 23:49 UTC

I principali Market Mover

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 gen 2026, 21:12 UTC

I principali Market Mover

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 gen 2026, 21:00 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 gen 2026, 20:29 UTC

I principali Market Mover

Chip Makers Gain After Trump Calls Off European Tariffs

21 gen 2026, 20:04 UTC

I principali Market Mover

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 gen 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 gen 2026, 23:34 UTC

Discorsi di Mercato

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 gen 2026, 22:39 UTC

Utili

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 gen 2026, 21:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

21 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

21 gen 2026, 21:35 UTC

Acquisizioni, Fusioni, Takeovers

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 gen 2026, 21:19 UTC

Utili

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 gen 2026, 20:45 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 gen 2026, 20:36 UTC

Discorsi di Mercato

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 gen 2026, 20:31 UTC

Discorsi di Mercato

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 gen 2026, 20:27 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 gen 2026, 20:27 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

21 gen 2026, 20:27 UTC

Discorsi di Mercato

Was It a 'TACO' Event? -- Market Talk

21 gen 2026, 20:26 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 gen 2026, 20:23 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 gen 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 gen 2026, 20:19 UTC

Acquisizioni, Fusioni, Takeovers

Deutsche Boerse Group Agrees to Buy Allfunds

21 gen 2026, 20:08 UTC

Utili

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 gen 2026, 20:03 UTC

Discorsi di Mercato

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 gen 2026, 19:51 UTC

Discorsi di Mercato

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 gen 2026, 19:43 UTC

Discorsi di Mercato

U.S. Ethanol Production Expected to Slip -- Market Talk

21 gen 2026, 19:31 UTC

Discorsi di Mercato

Gold Settles at Fresh All-Time High -- Market Talk

21 gen 2026, 19:24 UTC

Utili

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 gen 2026, 19:10 UTC

Discorsi di Mercato

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 gen 2026, 18:57 UTC

Discorsi di Mercato

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Confronto tra pari

Modifica del prezzo

Champions Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

71.43% in crescita

Previsioni per 12 mesi

Media 12 USD  71.43%

Alto 12 USD

Basso 12 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Champions Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

1 ratings

1

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

5.77 / 7.61Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Strong Bearish Evidence

Sentiment

By Acuity

177 / 360 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
help-icon Live chat